Efficacy of substituting innovator propafenone for its generic formulation in patients with atrial fibrillation

被引：9

作者：

Amit, G

Rosen, A

Wagshal, AB

Bonneh, DY

Liss, T

Grosbard, A

Ilia, R

Katz, A

机构：

[1] Ben Gurion Univ Negev, Soroka Univ Med Ctr, Electrophysiol Unit, Fac Hlth Sci, IL-84101 Beer Sheva, Israel

[2] Clalit Hlth Serv, Beer Sheva, Israel

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2004年 / 93卷 / 12期

关键词：

D O I：

10.1016/j.amjcard.2004.02.071

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

The clinical outcomes of 114 patients with atrial fibrillation who had been treated with the innovator propafenone, and in whom the drug was then replaced with generic propafenone because of cost containment, were compared. The generic formulation was found to be at least as safe and effective as the innovator drug, with regard to atrial fibrillation recurrence, emergency room and hospital admissions, and necessity for concomitant therapy. (C) 2004 by Excerpta Medica, Inc.

引用

页码：1558 / 1560

页数：3

共 11 条

[1]

CATELLUCI L, C CONSIDERS FUNDING

[2]

A retrospective assessment of safety, efficacy, and pharmacoeconomics of generic azathioprine in heart-transplant recipients [J].